Product image of Melkart Duo (Metformin Hydrochloride, Vildagliptin) supplied by GNH India

Melkart Duo

Active Ingredient:
Metformin Hydrochloride, Vildagliptin
Origin:
EU

Melkart Duo (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride and Vildagliptin, the active ingredients in Melkart Duo, are a Biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They are indicated for the management of type 2 diabetes mellitus in adults.
GNH India supplies Melkart Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melkart Duo is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect as adjunct therapy.
  • Combination with other antidiabetics: can be co‑prescribed with insulin or sulfonylureas to achieve target HbA1c.

How It Works

  • Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Vildagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased levels of endogenous incretins (GLP‑1 and GIP) that stimulate glucose‑dependent insulin secretion and suppress glucagon release.

Side Effects

Common side effects are generally mild and related to the gastrointestinal system or central nervous system.

Common Side Effects

  • Nausea: transient feeling of stomach upset.
  • Diarrhoea: loose stools, often mild.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional light‑headedness.
  • Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Allergic reactions: rash, pruritus, or angio‑edema.
  • Stevens‑Johnson syndrome: severe skin reaction.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for adverse events.

  • Renal function assessment: evaluate kidney function before starting and periodically thereafter.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Risk of hypoglycaemia: monitor blood glucose when combined with insulin or sulfonylureas.
  • Lactic acidosis warning: discontinue if signs such as muscle pain or rapid breathing appear.
  • Pregnancy and lactation: avoid unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Avoid Interactions

Melkart Duo may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycaemia.
  • Iodinated contrast agents: may impair renal function and raise metformin levels.
  • Strong CYP2C9 inhibitors: can affect vildagliptin metabolism.
  • Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Diuretics: may alter renal clearance of metformin.
  • Beta‑blockers: can mask symptoms of hypoglycaemia.
  • ACE inhibitors or ARBs: monitor renal function and electrolytes.
  • Rifampicin: may reduce plasma concentrations of vildagliptin.

Frequently Asked Questions

Melkart Duo is prescribed for the treatment of type 2 diabetes mellitus. It combines metformin, which reduces liver glucose production, with vildagliptin, which enhances insulin secretion in response to meals, helping patients achieve better glycaemic control when used alongside diet and exercise.

Metformin Hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, thereby reducing the amount of glucose released into the bloodstream. It also improves peripheral insulin sensitivity, allowing muscle and fat cells to take up glucose more efficiently.

The dosage of Melkart Duo is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Melkart Duo in pregnancy and lactation has not been established. It should generally be avoided unless the potential benefits outweigh the potential risks, and the decision should be made by a qualified healthcare provider.

To request Melkart Duo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melkart Duo offers a fixed‑dose combination of a Biguanide (metformin) and a DPP‑4 inhibitor (vildagliptin), providing complementary mechanisms of action. Compared with metformin alone, it adds post‑prandial glucose control, and compared with DPP‑4 inhibitor monotherapy, it includes the well‑established benefits of metformin on insulin sensitivity.

Melkart Duo tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Melkart Duo is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic condition linked to metformin, and severe hypoglycaemia, especially when used with insulin or sulfonylureas. Pancreatitis and serious allergic reactions are also rare but important to monitor.

Melkart Duo is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis. Caution is also advised in patients with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT